SLFN12 and breast cancer: CK-5 and P63 were picked because they are both markers of squamous cell carcinoma [3,30], and SFTPC, SCGB1A1, and HOPX are markers of LUAD [31], while CDH1 was picked because SLFN12 has been demonstrated to modulate CDH1 expression in prostate and breast cancers [12,13].